Retrophin, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$15.8M
Doctors Paid
6,335
Transactions
18,475
2019 Total
$4.2M
Payment Breakdown by Category
Research$12.9M (81.9%)
Consulting$1.1M (7.0%)
Food & Beverage$164,926 (1.0%)
Travel$139,838 (0.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $12.9M | 2,722 | 81.9% |
| Grant | $1.2M | 18 | 7.7% |
| Consulting Fee | $1.1M | 504 | 7.0% |
| Food and Beverage | $164,926 | 5,270 | 1.0% |
| Travel and Lodging | $139,838 | 452 | 0.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $133,563 | 76 | 0.8% |
| Education | $96,901 | 9,433 | 0.6% |
Payments by Type
Research
$12.9M
2,722 transactions
General
$2.9M
15,753 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| 021FSGS16010 | $1.4M | 13 | 705 |
| Evaluate the QT/QTc Interval Prolongation Potential of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, when Administered to Healthy Subjects: A Thorough Electrocardiographic Study | $1.3M | 0 | 3 |
| A PHASE 1, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS AND SAFETY OF SPARSENTAN (RE-021) IN MALE SUBJECTS WITH MILD OR MODERATE HEPATIC IMPAIRMENT COMPARED TO HEALTHY SUBJECTS | $1.3M | 0 | 21 |
| A Phase 1 Study of the Absorption, Metabolism, and Excretion of RE-024 in Healthy Subjects | $1.2M | 0 | 3 |
| DUET | $1.1M | 0 | 386 |
| 024PKAN15004 | $1.0M | 3 | 436 |
| EVALUATE THE QT/QTC INTERVAL PROLONGATION POTENTIAL OF SPARSENTAN (RE-021) WHEN ADMINISTERED TO HEALTHY SUBJECTS | $655,382 | 0 | 2 |
| 018CTXX15001 | $526,379 | 0 | 284 |
| A Phase 1, Double-blind, Randomized, Placebo-controlled, Sequential, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of RE-024 (Phosphopantothenate Replacement Therapy) in Healthy Subjects | $508,009 | 0 | 2 |
| Research Agreement | $499,492 | 0 | 6 |
| 021IGAN17001 | $363,691 | 11 | 293 |
| A RANDOMIZED, BLINDED, PLACEBO- AND ACTIVE-CONTROLLED STUDY TO EVALUATE THE QT/QTC INTERVAL PROLONGATION POTENTIAL OF SPARSENTAN (RE-021) WHEN ADMINISTERED TO HEALTHY SUBJECTS: A THOROUGH ELECTROCARDIOGRAPHIC STUDY | $259,551 | 0 | 2 |
| TQT Study - A Randomized, Double-blind, Placebo- and Active-controlled Study to Evaluate the QT/QTc Interval Prolongation Potential of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, when Administered to Healthy Subjects: A Thorough Electrocardiographic Study | $227,385 | 0 | 2 |
| A PHASE 1 STUDY TO INVESTIGATE THE ABSORPOTION, METABOLISM, AND EXCRETION OF [14]C-SPARSENTAN FOLLOWING A SINGLE ORAL DOSE IN HEALTHY MALE SUBJECTS | $222,106 | 0 | 4 |
| A PHASE 1, OPEN-LABEL, RANDOMIZED, 2-SEQUENCE, 3-PERIOD, PARTIAL CROSSOVER STUDY TO EVALUATE THE INDIVIDUAL EFFECTS OF CYCLOSPORIN AND ITRACONAZOLE ON THE SINGLE-DOSE SAFETY, TOLERABILITY, AND PHARMACOKINETIC PROFILE OF SPARSENTAN IN HEALTHY SUBJECTS | $186,631 | 0 | 2 |
| A SQUENCE RANDOMIZED CROSSOVER STUDY TO DETERMINE THE EFFECTS OF TRANSPORTER OATP1B1, 1B3 INHIBITION BY SPARSENTAN ON PITAVASTATIN PHARMACOKINETICS | $170,830 | 0 | 4 |
| The Replace Registry | $160,792 | 0 | 57 |
| A Food Effect Study with Sparsentan RE-021 | $152,292 | 0 | 1 |
| CTA Site Pmts-CTX Prevalence | $148,838 | 0 | 69 |
| Amendmnt #5 additional analysi | $147,748 | 0 | 2 |
| CTX Prevalence Study | $145,593 | 0 | 136 |
| A PROSPECTIVE, RANDOMIZED, OPEN-LABEL, NONREPLICATE CROSSOVER STUDY TO COMPARE THE BIOAVAILABILITY OF A TABLET FORMULATION OF SPARSENTAN (RE-021) TO A CAPSULE FORMULATION OF SPARSENTAN IN HEALTHY VOLUNTEER SUBJECTS | $120,389 | 0 | 1 |
| A PHASE I, MULTI-DOSE, TWO-PERIOD, OPEN LABEL, SINGLE-SEQUENCE, CROSSOVER STUDY TO EVALUATE CYP3A4 AND CYP2B6 INDUCTION BY SPARSENTAN | $120,389 | 0 | 1 |
| CROSSOVER STUDY TO EVALUATE THE INDIVIDUAL EFFECTS OF CYCLOSPORIN AND ITRACONAZOLE ON THE SINGLE-DOSE SAFETY, TOLERABILITY, AND PHARMACOKINETIC PROFILE OF SPARSENTAN IN HEALTHY SUBJECTS | $120,367 | 0 | 1 |
| FORT Study | $90,682 | 11 | 14 |
| CROSSOVER STUDY TO COMPARE THE BIOAVAILABILITY OF A TABLET FORMULATION OF SPARSENTAN (RE-021) TO A CAPSULE FORMULATION OF SPA | $87,254 | 0 | 2 |
| Crossover Study to Determine the Effects of P-gp Inhibition on the Pharmacokinetics of Fosmetpantotenate (RE-024), a Phosphopantothenate Replacement Therapy, in Healthy Subjects | $69,148 | 0 | 2 |
| CTX Prevalence 018CTXX15001 | $56,663 | 0 | 34 |
| Study of Cholic Acid Capsules | $52,524 | 0 | 2 |
| Protocol # RET-D-001 | $50,124 | 7 | 34 |
Payments by Medical Specialty
Top Paid Doctors — Page 3
| Doctor | Specialty | Location | Total | 2019 |
|---|---|---|---|---|
| Dr. Anne Pesenson, Md, MD | Nephrology | Seattle, WA | $6,846 | $0 |
| Hyder Jinnah, Md Phd, MD PHD | Neurology | Atlanta, GA | $6,609 | $0 |
| Maria Escolar | Pediatrics | Chapel Hill, NC | $6,493 | $0 |
| Dr. Erick Hernandez, Md, MD | Pediatric Gastroenterology | Miami, FL | $5,815 | $0 |
| Alan Pao, Md, MD | Internal Medicine | Stanford, CA | $5,775 | $0 |
| Dr. Hiral Shah, Md, MD | Neurology | New York, NY | $5,762 | $0 |
| Dr. James Carmody, Md, MD | Pediatrics | Norfolk, VA | $5,591 | $0 |
| Saul Karpen, Md, Phd, MD, PHD | Pediatric Gastroenterology | Atlanta, GA | $5,574 | $0 |
| Dr. Lisa Rich, M.d, M.D | Nephrology | Wauwatosa, WI | $5,566 | $0 |
| Dr. Brad Marder, Md, MD | Nephrology | Denver, CO | $5,512 | $0 |
| Dr. Philip Rosenthal, M.d, M.D | Pediatrics | San Francisco, CA | $5,147 | $0 |
| Dr. James Tumlin, M.d, M.D | Nephrology | Lawrenceville, GA | $5,078 | $0 |
| Ahmed Awad, Do, DO | Nephrology | Kansas City, MO | $5,044 | $0 |
| Dr. Vimal Derebail, M.d, M.D | Nephrology | Chapel Hill, NC | $5,044 | $0 |
| Prem Chandran, M.d, M.D | Nephrology | Des Moines, IA | $5,000 | $0 |
| Harold Szerlip, Md, MD | Internal Medicine | Charleston, SC | $4,953 | $0 |
| Sharon Adler, M.d, M.D | Nephrology | Torrance, CA | $4,927 | $0 |
| Dr. Ramakrishna Venkatesh, Md, MD | Urology | Saint Charles, MO | $4,801 | $0 |
| Dr. Michelle Semins, Md, MD | Urology | Pittsburgh, PA | $4,693 | $0 |
| Mantu Gupta, M.d, M.D | Specialist | New York, NY | $4,507 | $0 |
| Dr. Wayne Kotzker, Md, MD | Nephrology | Fort Lauderdale, FL | $4,148 | $0 |
| Dr. Kirk Campbell, M.d, M.D | Nephrology | New York, NY | $4,118 | $0 |
| Dr. David Sas, Do, DO | Pediatrics | Rochester, MN | $4,093 | $0 |
| Duncan Johnstone, Md, Phd, MD, PHD | Nephrology | Kansas City, KS | $4,012 | $0 |
| Dr. Marshall Stoller, M.d, M.D | Urology | San Francisco, CA | $4,000 | $0 |
Ad
Top Products
- (810) Chenodal $1.7M
- (820) Cholbam $745,631
Associated Products (3)
- (810) Chenodal $2.3M
- (815) Thiola $1.0M
- (820) Cholbam $1.0M
Payment Categories
- Food & Beverage $164,926
- Consulting $1.1M
- Travel & Lodging $139,838
- Research $12.9M
About Retrophin, Inc.
Retrophin, Inc. has made $15.8M in payments to 6,335 healthcare providers, recorded across 18,475 transactions in the CMS Open Payments database. In 2019, the company paid $4.2M. The top product by payment volume is (810) Chenodal ($1.7M).
Payments were distributed across 128 medical specialties. The top specialty by payment amount is Nephrology ($360,448 to 785 doctors).
Payment categories include: Food & Beverage ($164,926), Consulting ($1.1M), Research ($12.9M), Travel & Lodging ($139,838).
Retrophin, Inc. is associated with 3 products in the CMS Open Payments database.